Astria Therapeutics To Present Initial Navenibart ALPHA-STAR Data At The Upcoming European Academy Of Dermatology And Venereology Congress
Astria Therapeutics To Present Initial Navenibart ALPHA-STAR Data At The Upcoming European Academy Of Dermatology And Venereology Congress
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial navenibart ALPHA-STAR data at the upcoming European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, the Netherlands on September 26, 2024.
Astria Therapeutics，Inc.（纳斯达克：ATXS）是一家专注于开发过敏性和免疫性疾病的改变人生疗法的生物制药公司，今天宣布将于2024年9月26日在荷兰阿姆斯特丹举行的欧洲皮肤病学和性病学学会（EADV）大会上展示初步的Navenibart ALPHA-STAR数据。
Raffi Tachdjian, M.D., MPH, Associate Clinical Professor of Medicine and Pediatrics in the Division of Allergy and Clinical Immunology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), will present a poster titled "ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple Doses of STAR-0215 in Patients with Hereditary Angioedema: Initial Safety and Efficacy Outcomes." The poster will be presented in e-poster showcase six on Thursday, September 26 at 4:20pm CEST.
Raffi Tachdjian博士，MPH，毕业于加利福尼亚大学洛杉矶分校（UCLA）大卫·格芬医学院（David Geffen School of Medicine），是医学和儿科过敏和临床免疫学部的副临床教授，将在周四2024年9月26日下午4点20分CESt在电子海报展示区六上展示题为“ALPHA-STAR的海报”，STARS-0215在遗传性血管性水肿患者中单剂和多剂临床试验的初步安全性和疗效结果。”